Eagan Rt
Impact in
- Oncology top 10%
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 11
- Lung Cancer Diagnosis and Treatment 3
- Oncology 18
- Lung Cancer Research Studies 11
- Cancer Treatment and Pharmacology 4
- Co-authors
- Stephen Frytak (20 shared papers)Kvols Lk (10 shared papers)Carr Dt (4 shared papers)Edmonson Jh (4 shared papers)Robert G. Hahn (3 shared papers)Jonah Rubin (1 shared paper)O'Connell Mj (3 shared papers)Joseph Rubin (1 shared paper)
- Journals
- PubMed (29 papers)
- Partner nations
- United States
In The Last Decade
Eagan Rt
28 papers receiving 506 citations
Peers
Comparison fields: 5 of 57
- Oncology 396
- Pulmonary and Respiratory Medicine 258
- Epidemiology 141
- Cancer Research 54
- Pathology and Forensic Medicine 49
Countries citing papers authored by Eagan Rt
This map shows the geographic impact of Eagan Rt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eagan Rt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eagan Rt more than expected).
Fields of papers citing papers by Eagan Rt
This network shows the impact of papers produced by Eagan Rt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eagan Rt. The network helps show where Eagan Rt may publish in the future.
Co-authors
The 20 scholars most cited alongside Eagan Rt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer. | 1977 | 84 |
| 2 | Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. | 1975 | 54 |
| 3 | A case for preplanned thoracic and prophylactic whole brain radiation therapy in limited small-cell lung cancer. | 1981 | 52 |
| 4 | cis-Dichlorodiammineplatinum(II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung. | 1978 | 51 |
| 5 | VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. | 1978 | 43 |
| 6 | VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer. | 1976 | 43 |
| 7 | Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination. | 1983 | 31 |
| 8 | Thoracic radiation therapy and Adriamycin/cisplatin-containing chemotherapy for locally advanced non-small-cell lung cancer. | 1981 | 25 |
| 9 | Complications of treatment of small cell carcinoma of the lung. | 1983 | 23 |
| 10 | Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer. | 1976 | 22 |
| 11 | Phase II study on DON in patients with previously treated advanced lung cancer. | 1982 | 21 |
| 12 | Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation. | 1982 | 17 |
| 13 | Phase II trial of diaziquone in malignant mesothelioma. | 1986 | 16 |
| 14 | ICRF-159 versus polychemotherapy in non-small cell lung cancer. | 1976 | 15 |
| 15 | Phase II studies of polychemotherapy regimens in small cell lung cancer. | 1977 | 15 |
| 16 | Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers. | 1981 | 12 |
| 17 | Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report. | 1977 | 12 |
| 18 | Phase II evaluation of AMSA in patients with metastatic lung cancer. | 1980 | 11 |
| 19 | Early clinical trial of a 1-day intermittent schedule for pentamethylmelamine. | 1981 | 8 |
| 20 | Evaluation of VP-16-213, cyclophosphamide, doxorubicin, and cisplatin (V-CAP) in advanced large cell lung cancer. | 1981 | 7 |
About Eagan Rt
Eagan Rt is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Epidemiology and Hepatology, having authored 29 papers that have together received 598 indexed citations. Recurring topics across this work include Lung Cancer Research Studies (11 papers), Lung Cancer Treatments and Mutations (11 papers), Neuroendocrine Tumor Research Advances (6 papers), Cancer therapeutics and mechanisms (5 papers), Cancer Treatment and Pharmacology (4 papers), Lung Cancer Diagnosis and Treatment (3 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Head and Neck Cancer Studies (2 papers). The work is most often cited by research in Oncology (396 citations), Pulmonary and Respiratory Medicine (258 citations), Epidemiology (141 citations), Cancer Research (54 citations) and Pathology and Forensic Medicine (49 citations). Eagan Rt has collaborated with scholars based in United States. Frequent co-authors include Stephen Frytak, Kvols Lk, Carr Dt, Edmonson Jh, Robert G. Hahn, Jonah Rubin, O'Connell Mj, Joseph Rubin, Melanie J. Scott and Joshua T. Rubin. Their work appears in journals such as PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.